Allopregnanolone increases the number of dopaminergic neurons in substantia nigra of a triple transgenic mouse model of Alzheimer's disease

Current Alzheimer Research

Volumn 9, Issue 4, 2012, Pages 473-480

  Sun, Chenyou ^a,b   Ou, Xiaoming ^a   Farley, Jerry M ^a   Stockmeier, Craig ^a   Bigler, Steven ^a   Brinton, Roberta Diaz ^c   Wang, Jun Ming ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Allopregnanolone; Dopaminergic neurons; Neurogenesis; Substantia nigra; Tyrosine hydroxylase (TH)

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; BROXURIDINE; TYROSINE 3 MONOOXYGENASE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; MALE; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

EID: 84860519060     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720512800492567     Document Type: Article

References (73)

1. Mayeux R, Stern Y, Spanton S. Heterogeneity in dementia of the Alzheimer type: evidence of subgroups. Neurology 35: 453-461 (1985).
2. Jimenez-Escrig A, Rabano A, Guerrero C, Simon J, Barquero MS, Guell I, et al. New V272A presenilin 1 mutation with very early onset subcortical dementia and parkinsonism. Eur J Neurol 11: 663-669 (2004).
3. Jellinger KA. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution-a pilot study. Acta Neuropathol 106: 191-201 (2003).
4. Verny M, Duyckaerts C. Dementia with Lewy bodies. Ann Med Interne (Paris) 149: 209-215 (1998).
5. Gomez-Tortosa E, Ingraham AO, Irizarry MC, Hyman BT. Dementia with Lewy bodies. J Am Geriatr Soc 46: 1449-1458 (1998).
6. Mitsuyama Y. Presenile dementia with motor neuron disease. Dementia 4: 137-142 (1993).
7. Morris JC, Drazner M, Fulling K, Grant EA, Goldring J. Clinical and pathological aspects of parkinsonism in Alzheimer's disease. A role for extranigral factors? Arch Neurol 46: 651-657 (1989).
8. Jellinger K. Neuropathological substrates of Alzheimer's disease and Parkinson's disease. J Neural Transm Suppl 24: 109-129 (1987).
9. Kastner A, Hirsch EC, Herrero MT, Javoy-Agid F, Agid Y. Immunocytochemical quantification of tyrosine hydroxylase at a cellular level in the mesencephalon of control subjects and patients with Parkinson's and Alzheimer's disease. J Neurochem 61: 1024-1034 (1993).
10. McMillan PJ, White SS, Franklin A, Greenup JL, Leverenz JB, Raskind MA, et al. Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's disease. Brain Res 1373: 240-252 (2011).
11. Torack RM, Morris JC. Tyrosine hydroxylase-like (TH) immunoreactivity in Parkinson's disease and Alzheimer's disease. J Neural Transm Park Dis Dement Sect 4: 165-171 (1992).
12. Burns JM, Galvin JE, Roe CM, Morris JC, McKeel DW. The pathology of the substantia nigra in Alzheimer disease with extrapyramidal signs. Neurology 64: 1397-1403 (2005).
13. Kazee AM, Cox C, Richfield EK. Substantia nigra lesions in Alzheimer disease and normal aging. Alzheimer Dis Assoc Disord 9: 61-67 (1995).
14. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55: 306-319 (2004).
15. Kazee AM, Han LY. Cortical Lewy bodies in Alzheimer's disease. Arch Pathol Lab Med 119: 448-453 (1995).
16. Perez SE, Lazarov O, Koprich JB, Chen EY, Rodriguez-Menendez V, Lipton JW, et al. Nigrostriatal dysfunction in familial Alzheimer's disease-linked APPswe/PS1DeltaE9 transgenic mice. J Neurosci 25: 10220-10229 (2005).
17. O'Neil JN, Mouton PR, Tizabi Y, Ottinger MA, Lei DL, Ingram DK, et al. Catecholaminergic neuronal loss in locus coeruleus of aged female dtg APP/PS1 mice. J Chem Neuroanat 34: 102-107 (2007).
18. Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 24: 1063-1070 (2003).
19. Wang JM, Irwin RW, Liu L, Chen S, Brinton RD. Regeneration in a degenerating brain: potential of allopregnanolone as a neuroregenerative agent. Curr Alzheimer Res 4: 510-517 (2007).
20. Wang JM, Singh C, Liu L, Irwin RW, Chen S, Chung EJ, et al. Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 107: 6498-6503 (2010).
21. Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM. Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci 30: 7281-7289 (2010).
22. Baulieu EE, Robel P, Schumacher M. Neurosteroids: beginning of the story. Int Rev Neurobiol 46: 1-32. (2001).
23. Barha CK, Ishrat T, Epp JR, Galea LA, Stein DG. Progesterone treatment normalizes the levels of cell proliferation and cell death in the dentate gyrus of the hippocampus after traumatic brain injury. Exp Neurol 231: 72-81 (2011).
24. Djebaili M, Guo Q, Pettus EH, Hoffman SW, Stein DG. The neurosteroids progesterone and allopregnanolone reduce cell death, gliosis, and functional deficits after traumatic brain injury in rats. J Neurotrauma 22: 106-118 (2005).
25. Sayeed I, Guo Q, Hoffman SW, Stein DG. Allopregnanolone, a progesterone metabolite, is more effective than progesterone in reducing cortical infarct volume after transient middle cerebral artery occlusion. Ann Emerg Med 47: 381-389 (2006).
26. Wang JM, Brinton RD. Allopregnanolone-induced rise in intracellular calcium in embryonic hippocampal neurons parallels their proliferative potential. BMC Neurosci 9 Suppl 2: S11 (2008).
27. Wang JM, Johnston PB, Ball BG, Brinton RD. The neurosteroid allopregnanolone promotes proliferation of rodent and human neural progenitor cells and regulates cell-cycle gene and protein expression. J Neurosci 25: 4706-4718 (2005).
28. Wang J, Henry S, Hill R, Bigler S, Stockmeier C, Brinton RD, et al. Hippocampal Neural Progenitor Cell Proliferation Is More Sensitive to Estradiol in Mouse with an Arg-61 ApoE Mutation; 2010 July 10-July 15, 2010; Honolulu, USA.
29. Singh C, Liu L, Wang JM, Irwin RW, Yao J, Chen S, et al. Allopregnanolone restores hippocampal-dependent learning and memory and neural progenitor survival in aging 3xTgAD and nonTg mice. Neurobiology of Aging In press: (2011).
30. Chen S, Wang JM, Irwin RW, Yao J, Liu L, Brinton RD. Allopregnanolone Promotes Regeneration and Reduces beta-amyloid Burden in a Preclinical Model of Alzheimer's Disease. PLoS ONE Submitted: (2011).
31. McCormack AL, Atienza JG, Langston JW, Di Monte DA. Decreased susceptibility to oxidative stress underlies the resistance of specific dopaminergic cell populations to paraquat-induced degeneration. Neuroscience 141: 929-937 (2006).
32. Franklin K, Paxinos G. The mouse brain in stereotaxic coordinates. New York.: Academic Press (1997).
33. Dahlstrom A, Fuxe K. Localization of monoamines in the lower brain stem. Experientia 20: 398-399 (1964).
34. Bittner T, Fuhrmann M, Burgold S, Ochs SM, Hoffmann N, Mitteregger G, et al. Multiple events lead to dendritic spine loss in triple transgenic Alzheimer's disease mice. PLoS One 5: e15477 (2010).
35. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39: 409-421 (2003).
36. Wang JM, Singh C, Irwin WR, Liu L, Chen S, Thompson RF, et al. Allopregnanolone reverses the neurogenic and cognitive deficits of triple transgenic Alzheimer's mice; 2007 June 9-12, 2007; Washington D.C.
37. Wang JM, Sun C. Calcium and neurogenesis in Alzheimer's disease. Front Neurosci 4: 194 (2010).
38. Nelson EL, Liang CL, Sinton CM, German DC. Midbrain dopaminergic neurons in the mouse: computer-assisted mapping. J Comp Neurol 369: 361-371 (1996).
39. Chui HC, Mortimer JA, Slager U, Zarow C, Bondareff W, Webster DD. Pathologic correlates of dementia in Parkinson's disease. Arch Neurol 43: 991-995 (1986).
40. LaFerla FM, Troncoso JC, Strickland DK, Kawas CH, Jay G. Neuronal cell death in Alzheimer's disease correlates with apoE uptake and intracellular Abeta stabilization. J Clin Invest 100: 310-320 (1997).
41. Zarow C, Lyness SA, Mortimer JA, Chui HC. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 60: 337-341 (2003).
42. Snider BJ, Norton J, Coats MA, Chakraverty S, Hou CE, Jervis R, et al. Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life. Arch Neurol 62: 1821-1830 (2005).
43. Szot P, Van Dam D, White SS, Franklin A, Staufenbiel M, De Deyn PP. Age-dependent changes in noradrenergic locus coeruleus system in wild-type and APP23 transgenic mice. Neurosci Lett 463: 93-97 (2009).
44. German DC, Nelson O, Liang F, Liang CL, Games D. The PDAPP mouse model of Alzheimer's disease: locus coeruleus neuronal shrinkage. J Comp Neurol 492: 469-476 (2005).
45. Mudher A, Lovestone S. Alzheimer's disease-do tauists and baptists finally shake hands? Trends Neurosci 25: 22-26 (2002).
46. Mudher A, Shepherd D, Newman TA, Mildren P, Jukes JP, Squire A, et al. GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol Psychiatry 9: 522-530 (2004).
47. Schmitz C, Rutten BP, Pielen A, Schafer S, Wirths O, Tremp G, et al. Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. Am J Pathol 164: 1495-1502 (2004).
48. Gong CX, Iqbal K. Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr Med Chem 15: 2321-2328 (2008).
49. Iqbal K, Grundke-Iqbal I. Discoveries of tau, abnormally hyperphosphorylated tau and others of neurofibrillary degeneration: a personal historical perspective. J Alzheimers Dis 9: 219-242 (2006).
50. Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, SantaCruz K, et al. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci 25: 10637-10647 (2005).
51. Baulieu E, Schumacher M. Progesterone as a neuroactive neurosteroid, with special reference to the effect of progesterone on myelination. Steroids 65: 605-612 (2000).
52. Mellon SH, Gong W, Schonemann MD. Endogenous and synthetic neurosteroids in treatment of Niemann-Pick Type C disease. Brain Res Rev 57: 410-420 (2008).
53. Gago N, El-Etr M, Sananes N, Cadepond F, Samuel D, Avellana-Adalid V, et al. 3alpha,5alpha-Tetrahydroprogesterone (allopregnanolone) and gamma-aminobutyric acid: autocrine/paracrine interactions in the control of neonatal PSA-NCAM+ progenitor proliferation. J Neurosci Res 78: 770-783 (2004).
54. Keller EA, Zamparini A, Borodinsky LN, Gravielle MC, Fiszman ML. Role of allopregnanolone on cerebellar granule cells neurogenesis. Brain Res Dev Brain Res 153: 13-17 (2004).
55. Wang JM, Liu L, Irwin RW, Chen S, Brinton RD. Regenerative potential of allopregnanolone. Brain Res Rev 57: 398-409 (2008).
56. Marx CE, Trost WT, Shampine LJ, Stevens RD, Hulette CM, Steffens DC, et al. The Neurosteroid Allopregnanolone Is Reduced in Prefrontal Cortex in Alzheimer's Disease. Biol Psychiatry 60: 1287-1294. (2006).
57. Naylor JC, Kilts JD, Hulette CM, Steffens DC, Blazer DG, Ervin JF, et al. Allopregnanolone levels are reduced in temporal cortex in patients with Alzheimer's disease compared to cognitively intact control subjects. Biochim Biophys Acta 1801: 951-959 (2010).
58. Mellon SH, Griffin LD. Synthesis, regulation, and function of neurosteroids. Endocr Res 28: 463 (2002).
59. Yang SY, He XY, Schulz H. Multiple functions of type 10 17beta-hydroxysteroid dehydrogenase. Trends Endocrinol Metab 16: 167-175 (2005).
60. di Michele F, Longone P, Romeo E, Lucchetti S, Brusa L, Pierantozzi M, et al. Decreased plasma and cerebrospinal fluid content of neuroactive steroids in Parkinson's disease. Neurol Sci 24: 172-173 (2003).
61. Luchetti S, Bossers K, Frajese GV, Swaab DF. Neurosteroid biosynthetic pathway changes in substantia nigra and caudate nucleus in Parkinson's disease. Brain Pathol 20: 945-951 (2010).
62. Concas A, Mostallino MC, Porcu P, Follesa P, Barbaccia ML, Trabucchi M, et al. Role of brain allopregnanolone in the plasticity of gamma-aminobutyric acid type A receptor in rat brain during pregnancy and after delivery. Proc Natl Acad Sci U S A 95: 13284-13289 (1998).
63. Oberto A, Serra M, Pisu MG, Biggio G, Eva C. Changes in expression of the neuropeptide Y Y1 receptor gene in the medial amygdala of transgenic mice during pregnancy and after delivery. J Neurochem 82: 1272-1281 (2002).
64. Ahmad I, Lope-Piedrafita S, Bi X, Hicks C, Yao Y, Yu C, et al. Allopregnanolone treatment, both as a single injection or repetitively, delays demyelination and enhances survival of Niemann-Pick C mice. J Neurosci Res 82: 811-821 (2005).
65. Chen S, Wang JM, Irwin RW, Yao J, Liu L, Brinton RD. Allopregnanolone Promotes Regeneration and Reduces b-Amyloid Burden in a Preclinical Model of Alzheimer's Disease. Plos One 6: e24293 (2011).
66. Brinton RD, Wang JM. Preclinical analyses of the therapeutic potential of allopregnanolone to promote neurogenesis in vitro and in vivo in transgenic mouse model of Alzheimer's disease. Curr Alzheimer Res 3: 11-17 (2006).
67. Wang DD, Kriegstein AR, Ben-Ari Y. GABA Regulates Stem Cell Proliferation before Nervous System Formation. Epilepsy Curr 8: 137-139 (2008).
68. Hoglinger GU, Rizk P, Muriel MP, Duyckaerts C, Oertel WH, Caille I, et al. Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci 7: 726-735 (2004).
69. Zhao M, Momma S, Delfani K, Carlen M, Cassidy RM, Johansson CB, et al. Evidence for neurogenesis in the adult mammalian substantia nigra. Proc Natl Acad Sci U S A 100: 7925-7930 (2003).
70. Arias-Carrion O, Yamada E, Freundlieb N, Djufri M, Maurer L, Hermanns G, et al. Neurogenesis in substantia nigra of parkinsonian brains? J Neural Transm Suppl: 279-285 (2009).
71. Bjugstad KB, Teng YD, Redmond DE, Jr., Elsworth JD, Roth RH, Cornelius SK, et al. Human neural stem cells migrate along the nigrostriatal pathway in a primate model of Parkinson's disease. Exp Neurol 211: 362-369 (2008).
72. Luskin MB. Restricted proliferation and migration of postnatally generated neurons derived from the forebrain subventricular zone. Neuron 11: 173-189 (1993).
73. Rey NL, Jardanhazi-Kurutz D, Terwel D, Kummer MP, Jourdan F, Didier A, et al. Locus coeruleus degeneration exacerbates olfactory deficits in APP/PS1 transgenic mice. Neurobiol Aging 33: 426.e1-11 (2012).